SCHEMBL6733878

SCHEMBL6733878

COC(=O)c1ccc(OCC(=O)c2ccc3c(c2)C(C)(C)CCC3(C)C)c(I)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.71
CYP26A1 O43174 7/20 0.58
CYP26B1 Q9NR63 3/20 0.58
MAPT P10636 2/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
POLB P06746 1/20 0.42
BLM P54132 1/20 0.42
RXRA P19793 5/20 0.41
RXRB P28702 5/20 0.41
RARB P10826 5/20 0.41
RARG P13631 5/20 0.41
RXRG P48443 4/20 0.41
RARA P10276 4/20 0.41
MGLL Q99685 1/20 0.41
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6732613 0.91 CYP3A4 (0.71) CYP3A4CYP26A1CYP26B1MAPTLMNA
SCHEMBL8092497 0.89 CYP26A1 (0.70) CYP3A4CYP26A1CYP26B1RXRARXRB
SCHEMBL7898993 0.88 CYP3A4 (0.73) CYP3A4CYP26A1CYP26B1MAPTLMNA
SCHEMBL8101865 0.87 CYP3A4 (0.54) CYP3A4CYP26A1CYP26B1MAPTLMNA
SCHEMBL8093197 0.87 CYP3A4 (0.54) CYP3A4CYP26A1CYP26B1MAPTLMNA
SCHEMBL7898813 0.85 CYP3A4 (0.73) CYP3A4CYP26A1CYP26B1MAPTLMNA
SCHEMBL7900175 0.85 CYP3A4 (0.69) CYP3A4CYP26A1CYP26B1MAPTLMNA
SCHEMBL17914371 0.83 CYP3A4 (1.00) CYP3A4CYP26A1CYP26B1MAPTLMNA
SCHEMBL7900451 0.83 CYP3A4 (0.69) CYP3A4CYP26A1CYP26B1MAPTLMNA
SCHEMBL8086450 0.81 CYP3A4 (0.47) CYP3A4CYP26A1CYP26B1BLMRXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040162339-A1 Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof DIAZ PHILIPPE (FR) 2004-08-19 US disclosed
US-5981776-A FOR USE IN HUMAN OR VETERINARY MEDICINE (DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR AND OPHTHALMOLOGICAL COMPLAINTS IN PARTICULAR), OR ALTERNATIVELY IN COSMETIC COMPOSITIONS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 1999-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162339-A1 Heterocyclic biaryl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof TYR, MITF, CYP1B1 CYP3A4 147/4885CYP26A1 144/4885CYP26B1 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.